Table 2 Hazard ratios for overall survival
From: The impact of increasing dose on overall survival in prostate cancer
p-value | HR | 95 % CI | ||
|---|---|---|---|---|
Dose (Gy) | 68–69.99 | <0.001 | ≡1.00 | |
70–71.99 | 0.206 | 0.96 | [0.91, 1.02] | |
72–73.99 | <0.001 | 0.86 | [0.81, 0.92] | |
74–75.99 | <0.001 | 0.83 | [0.77, 0.90] | |
76–77.99 | <0.001 | 0.76 | [0.68, 0.84] | |
78–79.99 | <0.001 | 0.71 | [0.59, 0.84] | |
≥80 | <0.001 | 0.63 | [0.53, 0.76] | |
Androgen deprivation | No | -- | ||
Therapy | Yes | 0.009 | 0.94 | [0.90, 0.98] |
T stage | T1 | <0.001 | -- | |
T2 | <0.001 | 1.19 | [1.14, 1.25] | |
T3 | <0.001 | 1.40 | [1.29, 1.53] | |
T4 | <0.001 | 2.38 | [1.90, 2.97] | |
Grade | (1) Well Differentiated | <0.001 | -- | |
(2) Moderately Differentiated | 0.058 | 1.09 | [1.00, 1.20] | |
(3) Poorly Differentiated | <0.001 | 1.41 | [1.28, 1.56] | |
(4) Anaplastic | 0.001 | 1.78 | [1.25, 2.52] | |
Age | (Continuous) | <0.001 | 1.04 | [1.04,1.05] |
Marital status | Unmarried | -- | ||
Married | <0.001 | 0.80 | [0.76, 0.85] |